Cargando...
A Bayesian averted infection framework for PrEP trials with low number of HIV infections: application to the results of the DISCOVER trial
Trials of candidate agents for HIV pre-exposure prophylaxis (PrEP) may randomise between a new agent (nPrEP) and oral co-formulated emtricitabine plus tenofovir disoproxil fumerate (F/TDF). This design presents unique challenges in design and interpretation. First with two active arms, HIV incidence...
Gardado en:
| Publicado en: | Lancet HIV |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2020
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7664988/ https://ncbi.nlm.nih.gov/pubmed/33128906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3018(20)30192-2 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|